Compare ESP & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | CUE |
|---|---|---|
| Founded | 1928 | 2014 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 17.6M |
| IPO Year | 1995 | 2017 |
| Metric | ESP | CUE |
|---|---|---|
| Price | $56.20 | $0.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $64.00 | $3.00 |
| AVG Volume (30 Days) | 12.4K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | 31.88 | ★ 61.11 |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $43,950,872.00 | $27,466,000.00 |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | $105.00 |
| P/E Ratio | $32.43 | ★ N/A |
| Revenue Growth | 13.46 | ★ 195.75 |
| 52 Week Low | $24.85 | $0.17 |
| 52 Week High | $62.15 | $1.03 |
| Indicator | ESP | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 25.60 |
| Support Level | $52.83 | N/A |
| Resistance Level | $57.45 | $0.35 |
| Average True Range (ATR) | 2.36 | 0.02 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 78.84 | 4.09 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.